Your search history is turned on.
Date: April 29, 2024 Jurisdictions: Alberta
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...
Date: April 29, 2024 Jurisdictions: Alberta, British Columbia
Microsoft Word - _signed_ Q4 2023 CFO Cert - Hemostemix - April 2024(52491901.1).doc CAN: 52476366.1 1 3orm 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate I, Christina Wu, Interim Chief Financial Officer of Hemostemix Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD...
Microsoft Word - Q4 2023 CEO Cert - Hemostemix - April 2024(52476392.1).doc CAN: 52476392.1 1 Form 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate I, Thomas Smeenk, President and Chief Executive Officer of Hemostemix Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A...
Hemostemix - Q4 2023 - Final FS.pdf HEMOSTEMIX INC. CONSOLIDATED FINANCIAL STATEMENTS YEARS ENDED DECEMBER 31, 2023 AND 2022 (EXPRESSED IN CANADIAN DOLLARS) Independent Auditor's Report To the Shareholders of Hemostemix Inc.: Opinion We have audited the consolidated financial statements of Hemostemix Inc. and its subsidiaries (the "Company"...
Hemostemix - Q4 2023 - final MDA.pdf Hemostemix Inc. MANAGEMENTS DISCUSSION AND ANALYSIS OF THE RESULTS OF OPERATIONS AND FINANCIAL CONDITION For the year ended December 31, 2023 and 2022 as at April 29, 2024 BASIS OF PRESENTATION The following Managements Discussion and Analysis (MD&A) covers the operations, financial position and operating results...
Date: March 11, 2024 Jurisdictions: Alberta, British Columbia
Microsoft Word - 2024-003 Hemostemix Engages Oak Hill Final.docx Hemostemix Announces Engagement of Oak Hill Asset Management Inc. Calgary, Alberta, March 7, 2024, 2024 Hemostemix Inc. (Hemostemix or the Company) (TSXV: HEM; OTC: HMTXF) (FSE:2VF0) is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. (OHAM), an Exempt Market...
Date: February 6, 2024 Jurisdictions: Alberta, British Columbia
Microsoft Word - 2024-001 Hemostemix Phase 2 RCT CLTI Wound Healing Final.docx Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences Calgary, Alberta, February 6, 2024 Hemostemix Inc. (Hemostemix or the Company) (TSXV: HEM; OTC: HMTXF) (FSE:2VF0) is pleased to announc...
Date: January 3, 2024 Jurisdictions: Alberta, British Columbia
Microsoft Word - 2023-026 Hemostemix Clarifies October 3 2023 News Release.docx Hemostemix Clarifies its October 3, 2023 News Release Calgary, Alberta, December 29, 2023 Hemostemix Inc. (Hemostemix or the Company) (TSXV: HEM; OTC: HMTXF) (FSE:2VF0) is pleased to clarify its press release of October 3, 2023. It refered to the private placement of $320,125. Th...
Date: November 29, 2023 Jurisdictions: Alberta, British Columbia
Hemostemix Inc - Q3 2023 - FINAL MDA (11-29-2023).pdf Hemostemix Inc. MANAGEMENTS DISCUSSION AND ANALYSIS OF THE RESULTS OF OPERATIONS AND FINANCIAL CONDITION For the three and nine months ended September 30, 2023 and 2022 as at November 29, 2023 BASIS OF PRESENTATION The following interim Managements Discussion and Analysis (MD&A) covers the operation...
Hemostemix Inc - Q3 2023 - FINAL FS (11-29-2023).pdf HEMOSTEMIX INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Notice To Reader The accompanying unaudited condensed consolidated interim financial statements of Hemostemix Inc. (the "Company") have been ...